Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 1998

View Archived Issues

Company Profile: Alexion

Vitamin D3 analogues from Roche for skin, neoplastic diseases

BMS prepares MTP inhibitors for atherosclerosis and related diseases

Roche discloses inhibitors of bacterial dihydrofolate reductase

2,4-Diaminopyrimidines claimed as imaging agents, potentially useful in psychotic disorders

Synaptic develops selective human alpha1A-receptor antagonists

AMPA receptor antagonists disclosed by Pfizer

New anticonvulsants under study at Bristol-Myers Squibb

Somatostatin receptor ligands synthesized by Novo Nordisk

Structure of new IL-6 inhibitors determined at Kitasato Institute

Lipid peroxidation inhibitor discovered in marine sponge by team at Kirin Brewery and U. of Tokyo

OspC-based Lyme disease vaccine proves effective in animal model of chronic disease

Yamanouchi will collaborate on drug R&D with European universities

Antithrombotic agents in stroke indications

Mibefradil inhibits noradrenaline release via blockade of N-type Ca2+ channels

New wave of mergers in store for the pharmaceutical industry?

Glutamate antagonists: a new frontier in stroke research

VasoCare approved in EU

Bronchodilating and antiinflammatory effects of SCA-40 studied in vitro and in vivo

Xerecept shows promise in patients with brain tumors

Aurora sublicenses Sibia drug screening technology to Merck

RiboGene and Dainippon join forces in antibacterial collaboration

Controlled-release oxybutynin to be marketed in Europe by Synthelabo

CBER completes review of Thymoglobulin PLA

Topical interferon alfa enters phase II for intravaginal warts

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...